Journey Medical Corporation Quarterly report pursuant to Section 13 or 15(d)

INTEREST EXPENSE AND FINANCING FEES (Tables)

9 Months Ended

Sep. 30, 2021


	Three Months Ended September 30,
	2021						2020
($in thousands)	Interest		Fees¹		Total		Interest		Fees¹		Total
Convertible preferred shares	$	450	$	378	$	828	$	—	$	—	$	—
Dividend payable		365		—		365		—		—		—
Installment payments - licenses ²		170		—		170		187		—		187
Anti-itch product Note		10		—		10		—		—		—
Total Interest Expense and Financing Fee	$	995	$	378	$	1,373	$	187	$	—	$	187


	Nine Months Ended September 30,
	2021						2020
($in thousands)	Interest		Fees¹		Total		Interest		Fees¹		Total
Convertible preferred shares	$	1,034	$	648	$	1,682	$	—	$	—	$	—
Dividend payable		628		—		628		—		—		—
Installment payments - licenses ²		616		—		616		492		—		492
Anti-itch product Note		10		—		10		—		—		—
Total Interest Expense and Financing Fee	$	2,288	$	648	$	2,936	$	492	$	—	$	492

Note 1:Amortization of fees in connection with debt raises.

Note 2: Imputed interest expense related to Ximino, Accutane and anti-itch cream acquisitions.